Our top pick for
Masimo Corporation is a medical instruments & supplies business based in the US. Masimo Corporation shares (MASI) are listed on the NASDAQ and all prices are listed in US Dollars. Masimo Corporation employs 1,600 staff and has a trailing 12-month revenue of around USD$1.1 billion.
|52-week range||USD$143.9 - USD$259.29|
|50-day moving average||USD$240.5758|
|200-day moving average||USD$230.4267|
|Wall St. target price||USD$279.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$3.85|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Masimo Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Masimo Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Masimo Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 63x. In other words, Masimo Corporation shares trade at around 63x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Masimo Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.6475. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Masimo Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Masimo Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$279.1 million.
The EBITDA is a measure of a Masimo Corporation's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$1.1 billion|
|Operating margin TTM||22.99%|
|Gross profit TTM||USD$629.2 million|
|Return on assets TTM||10.4%|
|Return on equity TTM||17.64%|
|Market capitalisation||USD$13.5 billion|
TTM: trailing 12 months
There are currently 1.2 million Masimo Corporation shares held short by investors – that's known as Masimo Corporation's "short interest". This figure is 7.1% down from 1.3 million last month.
There are a few different ways that this level of interest in shorting Masimo Corporation shares can be evaluated.
Masimo Corporation's "short interest ratio" (SIR) is the quantity of Masimo Corporation shares currently shorted divided by the average quantity of Masimo Corporation shares traded daily (recently around 339584.89010989). Masimo Corporation's SIR currently stands at 3.64. In other words for every 100,000 Masimo Corporation shares traded daily on the market, roughly 3640 shares are currently held short.
However Masimo Corporation's short interest can also be evaluated against the total number of Masimo Corporation shares, or, against the total number of tradable Masimo Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Masimo Corporation's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Masimo Corporation shares in existence, roughly 20 shares are currently held short) or 0.0268% of the tradable shares (for every 100,000 tradable Masimo Corporation shares, roughly 27 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Masimo Corporation.
Find out more about how you can short Masimo Corporation stock.
We're not expecting Masimo Corporation to pay a dividend over the next 12 months.
Over the last 12 months, Masimo Corporation's shares have ranged in value from as little as $143.9 up to $259.29. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Masimo Corporation's is 0.8523. This would suggest that Masimo Corporation's shares are less volatile than average (for this exchange).
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. In addition, the company offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; and O3 regional oximetry for tissue oxygen saturation measurement. Further, it provides Patient SafetyNet, a surveillance, remote monitoring, and clinician notification solution; MyView, a wireless presence-detection system; and connectivity devices. Additionally, the company offers Trace, a patient data visualization and reporting software for Masimo Root and Radical-7 monitors. The company provides its products directly, as well as through distributors and original equipment manufacturers partners to hospitals, emergency medical service providers, physician offices, home care providers, long term care facilities, veterinarians, and consumers. Masimo Corporation was founded in 1989 and is headquartered in Irvine, California.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.